European Commission approves Astellas XOSPATA ™ for treatment of AML adult patients
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
yesterday, Invivoscribe, Incannounced that the European Commission (EC) has approved Astellas'Drug(http://XOSPATA ™ (gilteritinib) as a single therapy for treating adult patients with recurrent or refractory acute myeloid leukemia (AML)LeukoStratDetection(http://as a test menu service, available through Invivoscribe's sub-
company(http://LabPMM LLC (San Diego, California), LabPMM GmbH (Martins Reed, Germany) and LabPMM GK (Kawasaki, Japan)The LeukoStrat CDx FLT3 Mutation AssayReagent(http://box is currently available in Europe, Japan, Switzerland and Australia, with future launches in the US and ChinaInvivoscribe has partnered with Astellas to develop LeukoStrat CDx FLT3 Mutation Assay as an auxiliary diagnostic method to predict patients' reactions to Astellas pharmaceutical (http:// AML drug XOSPATA (gilteritinib fumarate) approval is based on the results of phase 3
(http:// of the ADMIRAL trial, which studied the effects of gilteritinib compared to remediation chemotherapy in patients with recurrent or refractory FLT3mut plus AML patients treated with gilteritinib had significantly longer total survival than patients receiving remediation chemotherapy The average total survival of patients treated with gilteritinib was 9.3 months, while the average total survival of patients receiving only remedial chemotherapy was 5.6 months
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
